William Blair Analysts Increase Earnings Estimates for TWST

Key Points

• William Blair raised its FY2025 earnings per share (EPS) estimate for Twist Bioscience from ($2.14) to ($1.98), indicating a more optimistic outlook for the company.
• In its latest quarterly results, Twist Bioscience reported an EPS of ($0.47), surpassing analyst expectations and generating $96.06 million in revenue.
• Analyst ratings for Twist Bioscience show a trend towards positivity, with an average rating of "Moderate Buy" and a price target of $49.40.

Twist Bioscience Corporation (NASDAQ:TWST - Free Report) - Research analysts at William Blair raised their FY2025 earnings per share (EPS) estimates for shares of Twist Bioscience in a report issued on Tuesday, August 5th. William Blair analyst M. Larew now expects that the company will earn ($1.98) per share for the year, up from their previous forecast of ($2.14). The consensus estimate for Twist Bioscience's current full-year earnings is ($2.12) per share. William Blair also issued estimates for Twist Bioscience's Q4 2025 earnings at ($0.34) EPS, Q1 2026 earnings at ($0.32) EPS, Q2 2026 earnings at ($0.29) EPS, Q3 2026 earnings at ($0.23) EPS, Q4 2026 earnings at ($0.16) EPS and FY2026 earnings at ($1.00) EPS.

TWST has been the subject of several other research reports. Guggenheim reiterated a "buy" rating and issued a $50.00 price target on shares of Twist Bioscience in a research report on Tuesday, May 6th. Robert W. Baird dropped their price target on Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating for the company in a research report on Tuesday, May 6th. JPMorgan Chase & Co. dropped their price target on Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating for the company in a research report on Tuesday, May 6th. Cowen reiterated a "buy" rating on shares of Twist Bioscience in a research report on Monday, August 4th. Finally, Evercore ISI set a $46.00 price objective on shares of Twist Bioscience in a research note on Monday, August 4th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, Twist Bioscience presently has an average rating of "Moderate Buy" and an average target price of $49.40.

Twist Bioscience Price Performance

NASDAQ:TWST traded up $1.42 on Thursday, reaching $27.06. 926,302 shares of the company's stock traded hands, compared to its average volume of 1,143,179. The stock has a 50-day simple moving average of $34.47 and a 200-day simple moving average of $37.89. Twist Bioscience has a 12 month low of $24.28 and a 12 month high of $55.33. The firm has a market cap of $1.63 billion, a PE ratio of -18.69 and a beta of 2.36. The company has a quick ratio of 3.60, a current ratio of 3.90 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The company reported ($0.47) EPS for the quarter, beating analysts' consensus estimates of ($0.54) by $0.07. The business had revenue of $96.06 million for the quarter, compared to analysts' expectations of $95.52 million. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%.

Institutional Trading of Twist Bioscience

Several large investors have recently bought and sold shares of TWST. Norges Bank purchased a new stake in shares of Twist Bioscience in the 4th quarter valued at approximately $7,584,000. Pictet Asset Management Holding SA lifted its holdings in shares of Twist Bioscience by 27.7% in the 4th quarter. Pictet Asset Management Holding SA now owns 8,131 shares of the company's stock worth $378,000 after acquiring an additional 1,764 shares during the last quarter. Alliancebernstein L.P. lifted its holdings in Twist Bioscience by 1.2% during the 4th quarter. Alliancebernstein L.P. now owns 66,524 shares of the company's stock worth $3,091,000 after buying an additional 820 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Twist Bioscience by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 1,374,667 shares of the company's stock worth $63,895,000 after buying an additional 6,908 shares in the last quarter. Finally, ExodusPoint Capital Management LP acquired a new stake in Twist Bioscience during the 4th quarter worth $1,826,000.

Insiders Place Their Bets

In other Twist Bioscience news, CFO Adam Laponis sold 2,449 shares of the company's stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $38.15, for a total value of $93,429.35. Following the completion of the transaction, the chief financial officer owned 103,569 shares in the company, valued at approximately $3,951,157.35. This represents a 2.31% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Patrick John Finn sold 1,877 shares of the company's stock in a transaction dated Wednesday, May 21st. The stock was sold at an average price of $29.75, for a total transaction of $55,840.75. Following the completion of the transaction, the chief operating officer owned 240,783 shares of the company's stock, valued at approximately $7,163,294.25. This trade represents a 0.77% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 13,109 shares of company stock valued at $425,962. 3.01% of the stock is currently owned by insiders.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.